ArticleThe patient2017
EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre.
Article in The patient, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 6 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Health-related quality of life in patients with cervical cancer: a systematic review and meta-analysis of EQ‑5D utility scores.Scientific reports · 2026Pooled it
- Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review.PharmacoEconomics - open · 2023Pooled it
- A Systematic Literature Review of Health Utility Values in Breast Cancer.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Pooled it
- Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer.PharmacoEconomics · 2020Pooled it
- Pooled it
- Implementing a Risk-Stratified National Breast Screening Programme in the United Kingdom: A Model-Based Cost-effectiveness Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Assessing the health utility values of patients with six common cancers in China using the QLU-C10D: A cross-sectional survey.iScience · 2026Article
- Examining the Association Between Equity-Related Factors and EQ-5D-3L Health Utilities of Patients with Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Health utility scores of six common cancers in China measured by SF-6Dv2.Health and quality of life outcomes · 2025Article
- Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.United European gastroenterology journal · 2023Article
- Quality of life of patients with hematological malignancies and factors affecting health state utility values.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Article
- Effect of Human-Oriented Fine Nursing on Psychological Emotion, Life Quality, and Nursing Satisfaction of Patients Undergoing Laparoscopic Radical Nephrectomy.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Cost-Effectiveness of a National Sugar-Sweetened Beverage Tax to Reduce Cancer Burdens and Disparities in the United States.JNCI cancer spectrum · 2020Article
- Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma.Journal of the National Cancer Institute · 2020Article
- Combined cancer patient-reported symptom and health utility tool for routine clinical implementation: a real-world comparison of the ESAS and EQ-5D in multiple cancer sites.Current oncology (Toronto, Ont.) · 2019Observational
- Health-related quality of life among cancer survivors in rural China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
- Quality of Life in Palliative Care.Expert review of quality of life in cancer care · 2017Article
- Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo improve the precision of health economics analyses in oncology, reference datasets of health utility (HU) scores are needed from cancer survivors across different disease sites. These data are particularly sparse amongst Canadian survivors.
methodsA survey was completed by 1759 ambulatory cancer survivors at the Princess Margaret Cancer Centre which contained demographic questions and the EuroQol-5D (EQ-5D) instrument. Clinical information was abstracted from electronic records and HU scores were calculated using Canadian health state valuations. Construct validity was assessed through correlation of HU and visual analog scale (VAS) scores (Spearman) and by comparing HU scores between performance status groups (effect size). The influence of socio-demographic clinical variables on HU was analyzed by non-parametric between-group comparisons and multiple linear regression.
resultsMean EQ-5D HU scores were derived for 26 cancers. Among all survivors, the mean ± standard error of the mean EQ-5D utility score was 0.81 ± 0.004. Scores varied significantly by performance status (p < 0.0001) and correlated with VAS (Spearman r = 0.61). The cancer sites with the lowest mean HU scores were acute lymphoblastic leukemia (0.70 ± 0.03) and pancreatic cancer (0.76 ± 0.03); testicular cancer (0.89 ± 0.02) and chronic lymphocytic leukemia (0.90 ± 0.05) had the highest mean scores. A multiple regression model showed that scores were influenced by disease site (p < 0.001), education level (p < 0.001), partner status (p < 0.001), disease extent (p = 0.0029), and type of most recent treatment (p = 0.0061).
conclusionsThis work represents the first set of HU scores for numerous cancer sites derived using Canadian preference weights. The dataset demonstrated construct validity and HU scores varied by general socio-demographic and clinical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.